Evidence map›Paper›PMID 40031949›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2025

Association of marginalization and PSMA-PET in prostate cancer An analysis of the Ontario PSMA-PET Registry for Recurrent Prostate Cancer.

Vivian S Tan, Ur Metser, Mohammed Rashid, Deanna L Langer, Pamela MacCrostie, Bo Green, Victor Mak, Girish S Kulkarni, Bobby Shayegan, Stephen Pautler and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Vivian S TanDepartment of Oncology, Western University, London, ON, Canada.
Ur MetserDepartment of Medical Imaging, University of Toronto, Toronto, ON, Canada.
Mohammed RashidClinical Institutes and Quality Programs, Ontario Health (Cancer Care Ontario), Toronto, ON, Canada.
Deanna L LangerClinical Institutes and Quality Programs, Ontario Health (Cancer Care Ontario), Toronto, ON, Canada.
Pamela MacCrostieClinical Institutes and Quality Programs, Ontario Health (Cancer Care Ontario), Toronto, ON, Canada.
Bo GreenClinical Institutes and Quality Programs, Ontario Health (Cancer Care Ontario), Toronto, ON, Canada.
Victor MakClinical Institutes and Quality Programs, Ontario Health (Cancer Care Ontario), Toronto, ON, Canada.
Girish S KulkarniDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Bobby ShayeganDepartment of Surgery, McMaster University, Hamilton, ON, Canada.
Stephen PautlerDepartment of Surgery, Western University, London, ON, Canada.
Luke T LavalléeDepartment of Urology, University of Ottawa, Ottawa, ON, Canada.
Antonio FinelliDepartment of Urology, University of Toronto, Toronto, ON, Canada.
Laurence KlotzDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Marlon HagertyDepartment of Radiation Oncology, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada.
Glenn BaumanDepartment of Oncology, Western University, London, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionProstate-specific membrane antigen-positron emission tomography (PSMA-PET) is a new standard for the imaging of high-risk or recurrent prostate cancer. While marginalization disparities exist for prostate cancer, less is known in the context of PSMA-PET. The objective of the study was to determine if marginalization was associated with access, PET positivity, management change, radiation use, and survival of prostate cancer in a universal healthcare system.

methodsPatients enrolled in the Ontario PSMA-PET Registry for Recurrent Prostate Cancer (PREP) between 2018 and 2022 were included. The Ontario Marginalization Index (material resources, racialized/newcomer, age/labor force, household/dwellings) was used. Outcomes included access, PET positivity, management change, radiation use, and survival. Cox proportional hazards and logistic regression models examined the association between marginalization and outcomes. Provincial administrative databases were leveraged to generate a diagnosis and a survivorship cohort of prostate cancer patients who received primary treatment to compare with the PSMA-PET cohort.

resultsThere were 4034 patients in the PSMA-PET cohort. Patients at higher material marginalization quintiles were under-represented in the PSMA-PET Registry Database. Similar under-representation was noted in the diagnosis (n=123 128) and survival (n=56 753) cohorts. Within the PSMA cohort, marginalization dimensions were not significantly correlated with PET positivity, management change, or radiation use.

conclusionsMarginalization quintiles across PSMA-PET access were similar in distribution to prostate cancer diagnoses and survivor cohorts. We found no association of marginalization with PET positivity, management change, or radiation use among those receiving PSMA-PET.

Identifiers

PMID40031949
PMCPMC12158457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.